NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03539601,"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged â‰¥ 2 Years, With Mild-moderate AD",https://clinicaltrials.gov/study/NCT03539601,,TERMINATED,"This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of age with mild-moderate AD.

A Sub-Study of Optical Coherence Tomography and Biomarkers in Subjects ages 2 to \<18 years old, with Mild to Moderate Atopic Dermatitis, treated with Crisaborole Ointment, 2% or Crisaborole Vehicle Ointment or Hydrocortisone Butyrate 0.1% Cream applied BID will also be conducted at select sites.",YES,Atopic Dermatitis,"DRUG: Crisaborole ointment, 2%|DRUG: Hydrocortisone butyrate cream, 0.1%|DRUG: Pimecrolimus cream, 1%|DRUG: Crisaborole Vehicle","Percent Change From Baseline in the Eczema Area and Severity Index (EASI) Total Score at Day 29, EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and percent (%) body surface area (%BSA) affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \[h\], upper limbs \[u\], trunk \[t\] \[including axillae, groin\], lower limbs \[l\] \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score (A) based upon %BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%), 6 (90 to 100%). Total EASI score (aged \>=8 years) =0.1\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et + It +Ext + Lt) + 0.4\*Al\*(El + Il + Exl + Ll); for aged 2 to \<8 years =0.2\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et +It + Ext + Lt) + 0.3\*Al\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity., Baseline, Day 29|Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Discontinuations Due to AEs and SAEs, An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. TEAEs are events between the first dose of study drug up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A SAE is any untoward medical occurrence at any dose that: results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event., From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)|Number of Participants With Local Tolerability Adverse Events (AEs), Local tolerability AEs included application and instillation site reactions, application site discharge, application site erythema, application site exfoliation, application site pain, application site pruritus, application site swelling, dermatitis and eczema, dermatitis atopic, dermatitis contact, eczema, skin irritation, telangiectasia and related conditions, and urticarias., From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)|Number of Participants With Clinically Significant Changes in Vital Signs, Vital sign measurements included temperature, respiratory rate, pulse rate, and blood pressure. Temperature, respiratory rate, pulse rate, and blood pressure were taken in the seated or supine position, after the participant has been sitting or lying calmly for a minimum of 5 minutes (when possible for younger children). Position of recording was consistent within participant through-out the study., Screening up to Day 29|Number of Participants With Clinically Significant Abnormal Laboratory Parameters, Hematology parameters included with criteria greater than (\>) 1.2\*upper limit of normal (ULN): leukocytes (10\^3 per cubic millimeter \[10\^3/mm\^3\]), lymphocytes (10\^3/mm\^3), lymphocytes/leukocytes (%), neutrophils (10\^3/mm\^3), neutrophils/leukocytes (%), basophils/leukocytes (%), eosinophils (10\^3/mm\^3), eosinophils/leukocytes (%), monocytes (10\^3/mm\^3), monocytes/leukocytes (%). Clinical chemistry included parameters: aspartate aminotransferase (units per liter \[U/L\]) (\>3.0\* ULN), alanine aminotransferase (U/L) (\>3.0\* ULN), alkaline phosphatase (U/L) (\>3.0\* ULN), creatinine (milligram per deciliter \[mg/dL\]) (\>1.3\* ULN), potassium (milliequivalent per liter \[mEq/L\]) (\>1.1\* ULN), bicarbonate (mEq/L) (\>1.1\* ULN)., Screening up to Day 29","Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Day 8, 15 and 22, EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and %BSA affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \[h\], upper limbs \[u\], trunk \[t\] \[including axillae, groin\], lower limbs \[l\] \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score(A) based upon %BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%), 6 (90 to 100%). Total EASI score (aged \>=8 years) =0.1\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et + It +Ext + Lt) + 0.4\*Al\*(El + Il + Exl + Ll); for aged 2 to \<8 years =0.2\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et +It + Ext + Lt) + 0.3\*Al\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity., Baseline, Day 8, 15 and 22|Number of Participants Who Achieved Success in the Investigator's Static Global Assessment (ISGA) (ISGA Score of Clear [0] or Almost Clear [1] With At-least a 2-Grade Improvement From Baseline) at Day 8, 15, 22 and 29, ISGA is a five point global assessment scale of AD severity, used to characterize participants' overall disease severity across all treatable AD lesions (excluding the scalp). ISGA score ranged from 0 to 4: where 0= clear (minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicated greater severity of AD., Day 8, 15, 22 and 29|Number of Participants Who Achieved Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) at Day 8, 15, 22 and 29, ISGA is a five point global assessment scale of AD severity, used to characterize participants' overall disease severity across all treatable AD lesions (excluding the scalp). ISGA score ranged from 0 to 4: where 0 = clear (minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicated greater severity of AD., Day 8, 15, 22 and 29|Number of Participants Who Achieved Greater Than or Equal to (>=) 75 Percent (%) Improvement From Baseline in Eczema Area and Severity Index (EASI) Total Score at Day 8, 15, 22 and 29, EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and %BSA affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \[h\], upper limbs \[u\], trunk \[t\] \[including axillae, groin\], lower limbs \[l\] \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score(A) based upon %BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%), 6 (90 to 100%). Total EASI score (aged \>=8 years) =0.1\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et + It +Ext + Lt) + 0.4\*Al\*(El + Il + Exl + Ll); for aged 2 to \<8 years =0.2\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et +It + Ext + Lt) + 0.3\*Al\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity., Day 8, 15, 22 and 29|Time to First Improvement From Baseline in Eczema Area and Severity Index (EASI) Total Score of Greater Than or Equal to (>=) 75%, EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and %BSA affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \[h\], upper limbs \[u\], trunk \[t\] \[including axillae, groin\], lower limbs \[l\] \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score(A) based upon %BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%), 6 (90 to 100%). Total EASI score (aged \>=8 years) =0.1\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et + It +Ext + Lt) + 0.4\*Al\*(El + Il + Exl + Ll); for aged 2 to \<8 years =0.2\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + Exu + Lu) + 0.3\*At\*(Et +It + Ext + Lt) + 0.3\*Al\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity., Baseline up to Day 43|Change From Baseline in Percent Body Surface Area (%BSA) at Day 8, 15, 22 and 29, Four body regions were evaluated: head and neck, upper limbs, trunk (including axillae) and lower limbs (including buttocks) excluding scalp. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand in a closed position) fitting in affected area of a body region was estimated. Maximum number of handprints were: 10 for head, neck (20 for \<8 years age), 20 for upper limbs, 30 for trunk, 40 for lower limbs (30 for \<8 years age). Surface area (SA) of body region equivalent to 1 handprint: 10% for head, neck (5% for \<8 years age), 5% for upper limbs, 3.33% for trunk, 2.5% for lower limbs (3.33% for \<8 years age). Overall %BSA for a body region = total number of handprints in a body region \* % SA equivalent to 1 handprint. % BSA for an individual: mean of % BSA of all 4 body regions, range =0-100%, higher values = greater AD severity., Baseline, Day 8, 15, 22 and 29|Change From Baseline in Peak Pruritus Numerical Rating Scale (NRS) in Participants Aged Greater Than or Equal to (>=) 12 Years at Day 8, 15, 22 and 29, The severity of itch (pruritus) due to AD was assessed using the peak pruritus NRS for participants aged \>=12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Baseline, Day 8, 15, 22 and 29|Change From Baseline in Participant Reported Itch Severity Scale in Participants Aged 6-11 Years at Day 8, 15, 22 and 29, The severity of itch (pruritus) due to AD was assessed using the five-category participant reported itch severity scale for participants aged 6-11 years. Participants at specified time points were asked to ""circle the face that shows how itchy your skin has been today"". The scale ranged from 0 to 4, where 0= no itch and 4= very itch. Higher scores indicated worse itch., Baseline, Day 8, 15, 22 and 29|Change From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years at Day 8, 15, 22 and 29, The severity of itch (pruritus) due to AD was assessed using the participant reported itch severity scale for participants aged \<6 years. Participant's caregivers at specified time points were asked the following question ""how would you rate your observation of your child's itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Baseline, Day 8, 15, 22 and 29|Time to Greater Than or Equal to (>=2) Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than (>) 12 Years, The severity of itch (pruritus) due to AD was assessed using the peak pruritus NRS for participants aged \>12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Baseline up to Day 29|Time to >= 3 Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than (>)12 Years, The severity of itch (pruritus) due to AD was assessed using the Peak Pruritus NRS for participants aged \>12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Baseline up to Day 29|Time >=2 Point to Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years, The severity of itch (pruritus) due to AD was assessed using the patient reported itch severity scale for participants aged \<6 years. Participant's caregivers at specified time points were asked the following question ""how would you rate your observation of your child's itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Baseline up to Day 29|Time to >=3 Point Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years, The severity of itch (pruritus) due to AD was assessed using the Patient Reported Itch Severity Scale for participants aged \<6 years. Participant's caregivers at specified time points were asked the following question ""how would you rate your observation of your child's itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Baseline up to Day 29|Number of Participants Who Achieved >=2 Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than or Equal to (>=) 12 Years at Day 8, 15, 22 and 29, The severity of itch (pruritus) due to AD was assessed using the peak pruritus NRS for participants aged \>=12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Day 8, 15, 22 and 29|Number of Participants Who Achieved >=3 Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than or Equal to (>=) 12 Years at Day 8, 15, 22 and 29, The severity of itch (pruritus) due to AD was assessed using the Peak Pruritus NRS for participants aged \>=12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Day 8, 15, 22 and 29|Number of Participants Who Achieved Greater Than or Equal to (>=) 2 Point Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years at Day 8, 15, 22 and 29, The severity of itch (pruritus) due to AD was assessed using the Patient Reported Itch Severity Scale for participants aged \<6 years. Participant's caregivers at specified time points were asked the following question ""how would you rate your observation of your child's itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Day 8, 15, 22 and 29|Number of Participants Who Achieved Greater Than or Equal to (>=) 3 Point Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years at Day 8, 15, 22 and 29, The severity of itch (pruritus) due to AD was assessed using the Patient Reported Itch Severity Scale for participants aged \<6 years. Participant's caregivers at specified time points were asked the following question ""how would you rate your observation of your child's itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch., Day 8, 15, 22 and 29|Change From Baseline in Dermatology Life Quality Index (DLQI) in Participants Greater Than or Equal to (>=) 16 Years at Day 8, 15, 22 and 29, DLQI is a 10-item questionnaire that measures the impact of skin disease on participants aged \>=16 years. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participant., Baseline, Day 8, 15, 22 and 29|Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) in Participants Aged 4-15 Years at Day 8, 15, 22 and 29, The CDLQI was a 10-item questionnaire that measures the impact of skin disease on children's (aged 4 to 15 years) quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The CDLQI total score was the sum of individual scores of question 1-10 and ranged from 0 (not at all) to 30 (very much): 0-1 = no effect on the child's life; 2-6 = small effect; 7-12 = moderate effect; 13-18 = very large effect; 19-30 = extremely large effect. Higher scores indicated more impact on quality of life of children., Baseline, Day 8, 15, 22 and 29|Change From Baseline in Dermatitis Family Impact Questionnaire (DFI) in Participants Aged 2-17 Years at Day 8, 15, 22 and 29, The DFI was a 10-item disease questionnaire that measures the impact of having a child (aged 2-17 years) with AD on family quality of life. It was completed by parent/legal guardian of the child (affected by AD), based on recall over the past week. Each question was scored on a 4-point scale ranging from 0 (not at all) to 30 (very much): where higher scores indicated worst quality of life of family. The DFI total score was the sum of individual scores of the 10 questions and ranged from 0 (no impact on life of family) to 30 (maximum effect on life of family), where higher DFI scores indicated maximum effect on life of family., Baseline, Day 8, 15, 22 and 29",,Pfizer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,237,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",C3291037|2018-001043-31,2018-04-27,2020-12-11,2020-12-11,2018-05-29,2021-12-08,2022-01-10,"Dermatology Trial Associates, Bryant, Arkansas, 72022, United States|California Dermatology & Clinical Research Institute, Encinitas, California, 92024, United States|Park Avenue Dermatology, Orange Park, Florida, 32073, United States|Lenus Research & Medical Group, LLC, Sweetwater, Florida, 33172, United States|ForCare Clinical Research, Tampa, Florida, 33613, United States|DS Research, Louisville, Kentucky, 40241, United States|M3-Wake Research, Inc., Raleigh, North Carolina, 27612, United States|Arlington Research Center, Inc., Arlington, Texas, 76011, United States|Tanner Clinic, Layton, Utah, 84041, United States|Virginia Clinical Research, Inc, Norfolk, Virginia, 23502, United States|Klinikum der Universitat Munchen, Munchen, Bayern, 80337, Germany|Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz, Bad Bentheim, Niedersachsen, 48455, Germany|Universitatsklinikum Bonn, Bonn, NRW, 53127, Germany|Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Schleswig-holstein, 23538, Germany|ISA - Interdisciplinary Study Association GmbH, Berlin, 10789, Germany|Universitaetsklinikum Frankfurt, Frankfurt am Main, 60590, Germany|UOSD Dermatologia Gen. ed Oncologica DU, PO San Salvatore, L'Aquila, AQ, 67100, Italy|DiSSal Sezione di Dermatologia Az. Ospedaliera Universitaria, Genova, GE, 16132, Italy|Ospedale San Pietro Fatebenefratelli, Roma, RM, 00189, Italy|Azienda Ospedaliero - Universitaria Policlinico Tor Vergata, Roma, Rome, 00133, Italy|Barbara Rewerska Diamond Clinic, Krakow, Malopolska, 31559, Poland|Silmedic sp. z o.o, Katowice, 40-282, Poland|Krakowskie Centrum Medyczne sp. z o.o., Krakow, 31-501, Poland|Klinika Ambroziak Sp. z O. O., Warszawa, 02-953, Poland|ROYALDERM Agnieszka Nawrocka, Warszawa, 02-962, Poland|Barn och Ungdomskliniken, Orebro, 701 85, Sweden|Avdelningen for Kliniska Provningar, Orebro, 703 62, Sweden|Universitatsklinik fuer Dermatologie, Bern, 3010, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 1004, Switzerland|Universitats-Kinderspital Zurich, Zurich, 8032, Switzerland|Rame Medical Ltd, Penntorr Health, Torpoint, Cornwall, PL11 2TB, United Kingdom|NHS Tayside, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/01/NCT03539601/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/01/NCT03539601/SAP_001.pdf"
